LITTLE ELM, Texas--(Business Wire)--
Retractable Technologies, Inc. (AMEX: RVP), a leading maker of safety needle
devices, announced today that a Marshall, Texas, jury returned a verdict
yesterday finding that all three patents asserted by Retractable Technologies,
Inc. ("the "Company") against Becton Dickinson and Company ("BD") are valid and
infringed. The jury also awarded damages to the Company in the amount of $5
million. The verdict, which can be appealed by either party, is directed against
BD`s infringing Integra® syringes.
Retractable Technologies, Inc. manufactures and markets safety medical products,
principally VanishPoint automated retraction safety syringes and blood
collection devices, that virtually eliminate healthcare worker exposure to
accidental needlestick injuries. These revolutionary devices use a patented
friction ring mechanism that causes the contaminated needle to retract
automatically, a feature that is designed to prevent both accidental needlestick
injury and device reuse. Retractable also manufactures and markets Patient Safe
syringes that are uniquely designed to reduce the risk of bloodstream infections
resulting from catheter hub contamination. Our products are distributed by
various specialty and general line distributors. For more information on
Retractable, visit our website at www.vanishpoint.com.
Forward-looking statements in this press release are made pursuant to the safe
harbor provision of the Private Securities Litigation Reform Act of 1995 and
reflect our current views with respect to future events. We believe that the
expectations reflected in such forward-looking statements are accurate. However,
we cannot assure you that such expectations will materialize. Our actual future
performance could differ materially from such statements.
Factors that could cause or contribute to such differences include, but are not
limited to: our ability to maintain liquidity; our maintenance of patent
protection; the impact of current litigation (as it affects our costs as well as
market access and the viability of our patents); the ability to maintain
favorable supplier arrangements and relationships; the ability to receive
royalties from Baiyin Tonsun Medical Device Co., Ltd.; our ability to quickly
increase capacity in the event of a dramatic increase in demand (such as by
increased orders due to swine flu vaccinations); our ability to access the
market; our ability to maintain or lower production costs; our ability to
continue to finance research and development as well as operations and expansion
of production;; and other risks and uncertainties that are detailed from time to
time in the Company`s periodic reports filed with the U.S. Securities and
Exchange Commission.
Retractable Technologies, Inc.
Douglas W. Cowan, 888-806-2626 or 972-294-1010
Vice President and Chief Financial Officer
rtifinancial@vanishpoint.com
Copyright Business Wire 2009
